(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD), Monday announced that the U.S. Food and Drug Administration has approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages ...

A newly approved option for pediatric patients with functional constipation significantly increased the frequency of bowel movements and improved other burdensome symptoms as well, according to a ...

Ironwood IRWD announced that the FDA has approved Linzess (linaclotide) as a once-daily treatment for functional constipation in pediatric patients aged 6-17 years. This approval for the new ...

The phase 3 trial included patients 6 to 17 years of age who fulfilled modified Rome III Criteria for child/adolescent functional constipation. Treatment with linaclotide improved the frequency of ...

Ironwood Pharmaceuticals IRWD announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation (FC) ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...

Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...

Please provide your email address to receive an email when new articles are posted on . AbbVie announced that it has submitted a supplemental new drug application for Linzess for the treatment of ...